Drug Delivery Business

Philip Morris and Carlyle continue bidding war over Vectura

By

Philip Morris/Vectura/Carlyle GroupThe drama surrounding the inhalable drug delivery specialist Vectura (LON:VEC) continues.

On Monday, Philip Morris boosted its offer to acquire Vectura to 165 pence ($2.30) per share, beating Carlyle’s latest offer of 155 pence ($2.16).

In July, Philip Morris (NYSE:PM) agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion, drawing criticism from the American Lung Association, British Thoracic Society and other health organizations.

Get the full story from our sister site Pharmaceutical Processing World. 

IN CASE YOU MISSED IT

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].